IGCS19-0417

170 PATTERNS OF RECURRENCE AFTER ROBOTIC-ASSISTED RADICAL HYSTERECTOMY (RRH) FOR EARLY STAGE CERVICAL CANCER (CC)

C Fitzsimmons*, A Stephens, J Kennard, M Manyam, J Pepe, K DeCoff, S Ahmad, N McKenzie, J Kendrick, R Holloway, AdvarHealth Cancer Institute, Gynecologic Oncology, Orlando, USA

10.1136/ijgc-2019-IGCS.170

Objectives To evaluate the recurrence patterns of early CC following RRH.

Methods Patients with early-stage CC (4/2007–12/2017) who underwent RRH using a uterine manipulator were evaluated. Inclusion criteria: > one year follow-up, adenocarcinoma or squamous carcinoma, stage IA2 or IB1 using FIGO-2014 guidelines, and pathologic tumor size (TS) of ≥4 cm. Results 144 RRH patients were identified and 90 met inclusion criteria. Baseline characteristics included: TS ≥2 cm 42 (47%), and adenocarcinoma 40 (44%). There were 7 (7.8%) recurrences with median time to recurrence of 12±8.3 months. All and adenocarcinoma 40 (44%). There were 7 (7.8%) recurrences compared to 28 squamous with 2 (7%) recurrences with median time to recurrence of 12±8.3 months. All recurrences had TS ≥2 cm (median 2.7±0.7 cm). Of the 42 cases with TS ≥2 cm, 14 had adenocarcinoma with 5 (36%) recurrences compared to 28 squamous with 2 (7%) recurrences (p=0.057). Three recurrences had carcinomatosis with mean RFS and OS of 5.3±2.3 and 28.3±30.9 months compared to 17.8±6.3 and 80.6±48.6 months for cases with local/pulmonary metastasis (n=4). RFS with carcinomatosis was less than RFS for local/pulmonary (p=0.014). Six recurrences occurred within the first 10 RRH cases per surgeon.

Conclusions Early-stage CC treated with RRH appears to have a unique pattern of recurrence in some cases with carcinoma-tosis that results in shortened RFS. Recurrences were associated with adenocarcinoma, TS ≥2 cm, and first 10 cases of surgeon experience. Carcinomatosis may be related to negative insufflation following colpotomy, requiring a new strategy that isolates the cervical tumor prior to colpotomy.

IGCS19-0675

172 GASTRIC-TYPE ENDOCERVICAL ADENOCARCINOMA (GAS): A COMPARATIVE ANALYSIS

D Cantu, L Gallardo-Alvarado*, C Perez-Plascencia, MD Perez-Montiel, O Millan-Catalan, LA Herrera-Montalvo. Instituto Nacional de Cancerologia, Direction of Research, Mexico City, Mexico; Instituto Nacional de Cancerologia, Laboratory of Genomics, Mexico City, Mexico; Instituto Nacional de Cancerologia, Department of Pathology, Mexico City, Mexico

10.1136/ijgc-2019-IGCS.172

Objectives Compare clinical outcomes of GAS, usual-type endocervical adenocarcinomas (UEA) and squamous cell carcinoma (SCC).

Methods Twenty-two cases of GAS, 44 cases of UEA and 66 cases of SCC matched by age and clinical stage were assessed. Diagnosis of GAS was based on the Kojima's criteria and immunohistochemical results. Clinical parameters (age, clinical stage and clinical outcome after first-line treatment) were recorded. Descriptive and comparative analysis was conducted. Response to treatment was compared between groups. Overall Survival (OS) and Disease-Free survival (DFS) were calculated with Kaplan-Meier method, compared with Log-Rank test.

Results Mean age at diagnosis was 51 years (range 31–76). Five cases were clinical stage IB1 (22.7%), IB2 1 (4.5%), IIB 2 (9.1%), IIB 4 (18.2%), IVA 2 (9.1%), IVB 8 (36.4%). The median follow-up was 23 months. GAS cases showed complete response to first-line treatment in 31.1% (n=7), partial response 18.2% (n=4), 40.9% (n=9) had persistence/progres-sion of the disease, no statistical difference was observed when compared to other histologies (p=0.2). Progression-free survival was 85.7% without significant difference (p=0.9). The overall survival was 75% at 24 months, and comparable to SCC and UEA (p=0.6).

IGCS19-0616

171 IDENTIFICATION OF THE FORMS OF USE AND ACCESS TO INFORMATION USED BY PATIENTS IN TREATMENT OF CERVICAL CANCER

B Franca*, R Samantha Martelet David, A Correia Gentil Filho, V Oliveira Rezende Sant’ana, M Souza Cerveira Pereira, A Campana Correia Leite. Universidade Nilton Lins, Medicina, Manaus, Brazil; Universidade Federal do Amazonas, Medicine, Manaus, Brazil

10.1136/ijgc-2019-IGCS.171

Abstract 170 Table 1

<table>
<thead>
<tr>
<th>MT</th>
<th>Tumor Size (cm)</th>
<th>UTV</th>
<th>MHTV</th>
<th>Node</th>
<th>Vaginal Margin</th>
<th>Grade</th>
<th>Histology</th>
<th>Prof</th>
<th>Carcinomatosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-6</td>
<td>1.7±1.5</td>
<td>44</td>
<td>50%</td>
<td>15</td>
<td>10%</td>
<td>4.4</td>
<td>2a ± 2b, c</td>
<td>Ancaron: 40%, Squam: 50, 56%</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2</td>
<td>Squamous</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>2</td>
<td>Adenocarcinoma</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2.5</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>1</td>
<td>Squamous</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2.5</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>1</td>
<td>Adenocarcinoma</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>3</td>
<td>Adenocarcinoma</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>2.5</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>3</td>
<td>Adenocarcinoma</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>3</td>
<td>Adenocarcioma</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>3</td>
<td>Adenocarcinoma</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

Conclusions Early-stage CC treated with RRH appears to have a unique pattern of recurrence in some cases with carcinomatosis that results in shortened RFS. Recurrences were associated with adenocarcinoma, TS ≥2 cm, and first 10 cases of surgeon experience. Carcinomatosis may be related to negative insufflation following colpotomy, requiring a new strategy that isolates the cervical tumor prior to colpotomy.
IGCS19-0503

EXPERIENCE WITH CONCURRENT CHEMORADIOThERAPY TREATMENT IN ADVANCED CERVICAL CANCER: RESULTS OF A HOSPITAL IN ARGENTINA

1'M Giavedoni, 2'S Lucas, 1'S Rosa*, 2'B Cintia, 2'S Mabel, 1'M Perrotta. 1'Hospital Italiano de Buenos Aires, Ginecologia Oncologica, Buenos Aires, Argentina; 2'Hospital Italiano de Buenos Aires, Oncologia Radiante, Buenos Aires, Argentina

10.1136/ijgc-2019-IGCS.173

Objectives Describe our experience with concurrent chemoradiotherapy (CCRT) using three-dimensional conformal pelvic radiotherapy (3D-CRT) and high dose rate intracavitary brachytherapy (HDR-ICBT) with weekly cisplatin in the treatment of patients with low advanced uterine cervical cancer.

Methods Forty tree patients were identified between January 2009 and December 2015. We retrospectively reviewed their medical records and data on patients’ characteristics, tumor, treatment and toxicities were collected and analyzed.

Results The median age was 45 years old (IR: 26). The median tumor size was 45 mm (IR: 20). Thirty-eight patients (88%) had cervical tumor size ≥40 mm. The median cervical tumor size assessed by MRI was 52 mm (IR: 17). Twenty-two patients (51%) had enlarge nodes on MRI (≥10 mm). The MRI showed involvement of the parametrium in twenty-nine patients (51%). Fifteen patients had positives paraaortic nodes (36%). The median overall treatment time was 58 days (IR: 20). Seventeen patients (39%) received extended field radiotherapy. Cisplatin was concurrent administered for a median of 5 courses. The median follow up period was 32 months (IR: 28 months). Acute gastrointestinal grade 3 toxicity was observed in seven patients (16%). Late grade 3/4 toxicity was observed in fourteen patients (33%). Seven patients (16%) persisted with disease and five of them died. The local relapse rate was 9%. Eleven patients underwent hysterectomy after treatment. The disease free interval was 24.2 months. The disease-free interval was 24.2 months. The local relapse observed in seven patients (16%). Late grade 3/4 toxicity was observed in seven patients (16%).

Conclusions Concurrent chemoradiotherapy appears to be effective regimen for patients with low advanced cervical cancer with acceptable toxicity.

IGCS19-0234

ONCOLOGY IN A BENIGN GYNECOLOGY DEPARTMENT

K. Glennon*, S Cleary, G Von Banau. Tallaght University Hospital, Cervical Check Colposcopy Department, Dublin, Ireland

10.1136/ijgc-2019-IGCS.175

Objectives To assess the extent the contribution of a gynaecological service in a non-designated hospital makes to the investigation of cancer. Assessment of the imaging and histopathology work up of cancer patients prior to referral or transfer to a dedicated gynaec-oncology centre.

Methods This was a retrospective cohort study concentrating on all cancer diagnoses in a benign gynaecological unit from 2012–2018. Patients were identified from the department archive of referrals to the gynaec-oncology department, the histopathology SNOWMED system and radiological database. The patient data was analysed using Microsoft excel

Results Since 2012 – December 2018, 239 cases of endometrial or cervical cancer were diagnosed (endometrial=125 cervical=113). The mean age of cervical cancer patients was 44 years (29 – 84) and endometrial cancer patients was 63 years (41 – 88). Ninety percent of patients had imaging prior to transfer to the gynaec-oncology department (MRI=105, CT-TAP=112). Suspicious complex ovarian masses diagnosed on CT or MRI also required MDT discussion (2018 n=33). The patients were referred to the gynaecology MDT in the tertiary system following complete work up.

IGCS19-0230

LOW-DOSE DAILY ORAL METRONIDAZOLE IS ASSOCIATED WITH A REDUCTION IN MALIGNANT FISTULAE IN LOWLY RECURRENT CERVICAL CANCER: RESULTS FROM A TEN-YEAR HISTORIC COHORT

1'RM George*, 1‘SP Thotampuri, 1‘R Kandasamy, 1‘S Murali, 2‘R Rekha, 2‘T Mani. 1‘Christian Medical College, Palliative Care Unit, Vellore, India; 2‘Christian Medical College, Biostatistics, Vellore, India

10.1136/ijgc-2019-IGCS.174

Objectives We wished to assess if low-dose daily oral metronidazole reduced the risk of malignant vesico-vaginal (VVF) and recto-vaginal fistulae (RVF) in recurrent cervical cancer.

Methods From a ten-year historic cohort in our teaching hospital, we identified 208 patients with pelvic recurrence of cervical cancer. Seventy six patients had been prescribed oral metronidazole 200 mg once daily for malodor control. We compared fistula-free survival and post-recurrence survival in patients who had received, or not received, low dose (metronomic) metronidazole.

Results Seventy two patients developed malignant fistulae (49 VVFs; 10 RVFs and 13 with both VVF and RVF). Metronomic metronidazole was associated with fewer fistulae (22.4% versus 41.7%); a longer fistula-free survival [42.9 months (95% CI, 10.2 m to 75.6 m); versus 14.1 months (95% CI, 7.7 m to 20.4 m); P<0.001]; and a trend to improved post-recurrence survival.

In the subset (n=146) followed until death, on multivariate analysis, metronomic metronidazole remained significantly associated with a longer post-recurrence survival [hazard ratio 0.56; 95% CI, 0.39–0.81; P=0.002] and a longer fistula-free survival [hazard ratio 0.34; 95% CI, 0.17–0.69; P=0.003].

Conclusions Daily low-dose oral (metronomic) metronidazole is a simple and inexpensive intervention. Reduction in inflammation, malodor and necrotic discharge, and decreased liquefactive destruction of visceral tissue planes probably led to better fistula and survival outcomes in this retrospective study.

Our findings suggest that it would be worthwhile to conduct a randomized trial comparing fistula, malodor, radiotherapy completion, local control and survival outcomes in recurrent or locally advanced cervical cancer with or without metronomic metronidazole.